Dermata Therapeutics Inc Cash Flow-to-Debt Ratio
Dermata Therapeutics Inc cash flow-to-debt ratio. Dermata Therapeutics Inc (DRMA) has a Cash Flow-to-Debt Ratio of -1.32x as of June 2026, meaning its operating cash flow of $-2.42 Million could theoretically repay -1% of its total liabilities ($1.83 Million) in one year. See Dermata Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Dermata Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Dermata Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Dermata Therapeutics Inc across 7 annual periods. Also explore Dermata Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Dermata Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Dermata Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Dermata Therapeutics Inc. For the full cash flow conversion analysis, see DRMA cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4728.93x | $-7.76 Billion | $1.64 Million | ▼ -83473.0% |
| 2024 | -5.66x | $-11.16 Million | $1.97 Million | ▼ -43.3% |
| 2023 | -3.95x | $-6.41 Million | $1.62 Million | ▲ +58.8% |
| 2022 | -9.57x | $-8.83 Million | $922.63K | ▼ -155.1% |
| 2021 | -3.75x | $-5.69 Million | $1.52 Million | ▼ -252.5% |
| 2020 | -1.06x | $-4.03 Million | $3.78 Million | ▲ +38.2% |
| 2019 | -1.72x | $-3.92 Million | $2.28 Million | — |